Compare Stocks: VERU, IMUX, LFCR, and NRXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$10.37 -7.7%	$14.51	$5.06 ▼ $17.43	$153.23M	1.41	268,774 shs	287,348 shs
LFCR Lifecore Biomedical	$4.14 -2.6%	$4.52	$3.63 ▼ $8.98	$160.88M	1.08	133,293 shs	76,083 shs
NRXP NRx Pharmaceuticals	$3.40 -2.6%	$3.61	$1.62 ▼ $5.05	$151.10M	2.19	618,134 shs	1.26 million shs
VERU Veru	$2.34	$2.51	$2.05 ▼ $7.33	$39.90M	-1.17	220,441 shs	125,287 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	-7.66%	-18.60%	-35.43%	-26.97%	+34.12%
LFCR Lifecore Biomedical	-2.59%	-3.94%	-12.29%	-25.00%	-46.09%
NRXP NRx Pharmaceuticals	-2.58%	-2.02%	+3.98%	-14.57%	+13.33%
VERU Veru	0.00%	-9.30%	-14.29%	-21.74%	-33.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$10.37 -7.7%	$14.51	$5.06 ▼ $17.43	$153.23M	1.41	268,774 shs	287,348 shs
LFCR Lifecore Biomedical	$4.14 -2.6%	$4.52	$3.63 ▼ $8.98	$160.88M	1.08	133,293 shs	76,083 shs
NRXP NRx Pharmaceuticals	$3.40 -2.6%	$3.61	$1.62 ▼ $5.05	$151.10M	2.19	618,134 shs	1.26 million shs
VERU Veru	$2.34	$2.51	$2.05 ▼ $7.33	$39.90M	-1.17	220,441 shs	125,287 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	-7.66%	-18.60%	-35.43%	-26.97%	+34.12%
LFCR Lifecore Biomedical	-2.59%	-3.94%	-12.29%	-25.00%	-46.09%
NRXP NRx Pharmaceuticals	-2.58%	-2.02%	+3.98%	-14.57%	+13.33%
VERU Veru	0.00%	-9.30%	-14.29%	-21.74%	-33.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMUX Immunic	3.00	Buy	$47.25	355.64% Upside
LFCR Lifecore Biomedical	2.00	Hold	$6.50	57.00% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	914.71% Upside
VERU Veru	2.33	Hold	$24.50	947.01% Upside

Current Analyst Ratings Breakdown

Latest VERU, IMUX, LFCR, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/10/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
9/10/2026	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
9/9/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
LFCR Lifecore Biomedical	$128.87M	1.22	N/A	N/A	$0.42 per share	9.86
NRXP NRx Pharmaceuticals	$1.23M	119.69	N/A	N/A	($0.54) per share	-6.30
VERU Veru	N/A	N/A	N/A	N/A	$1.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
LFCR Lifecore Biomedical	N/A	-$1.07	N/A	N/A	N/A	-29.93%	N/A	-16.16%	10/2/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)

Latest VERU, IMUX, LFCR, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
8/5/2026	Q2 2026	LFCR Lifecore Biomedical	-$0.19	-$0.19	N/A	-$0.19	$34.18 million	$34.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMUX Immunic	N/A	5.05	5.05
LFCR Lifecore Biomedical	N/A	3.87	2.69
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
VERU Veru	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMUX Immunic	51.82%
LFCR Lifecore Biomedical	83.36%
NRXP NRx Pharmaceuticals	4.27%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
IMUX Immunic	5.49%
LFCR Lifecore Biomedical	32.68%
NRXP NRx Pharmaceuticals	6.40%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMUX Immunic	95	13.64 million	12.90 million	Optionable
LFCR Lifecore Biomedical	382	37.85 million	25.48 million	Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable
VERU Veru	230	17.05 million	14.63 million	Optionable

VERU, IMUX, LFCR, and NRXP Headlines

Recent News About These Companies

Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

September 8, 2026 | rttnews.com

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...

September 8, 2026 | finance.yahoo.com

Veru refocuses sabizabulin on post-daraxonrasib oncology

September 8, 2026 | tipranks.com

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

September 8, 2026 | quiverquant.comQ

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Veru (VERU) Q3 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10, 2026 | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10, 2026 | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10, 2026 | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026 | globenewswire.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

Veru Establishes At-the-Market Equity Offering Program

July 2, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU, IMUX, LFCR, and NRXP Company Descriptions

Immunic NASDAQ:IMUX

$10.37 -0.86 (-7.66%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$10.37 0.00 (-0.01%)

As of 09/15/2026 07:43 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Lifecore Biomedical NASDAQ:LFCR

$4.14 -0.11 (-2.59%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$4.15 +0.01 (+0.22%)

As of 09/15/2026 07:30 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

NRx Pharmaceuticals NASDAQ:NRXP

$3.40 -0.09 (-2.58%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$3.34 -0.06 (-1.65%)

As of 09/15/2026 07:51 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Veru NASDAQ:VERU

$2.34 0.00 (0.00%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.40 +0.06 (+2.56%)

As of 09/15/2026 07:57 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERU, IMUX, LFCR, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERU, IMUX, LFCR, and NRXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERU, IMUX, LFCR, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU, IMUX, LFCR, and NRXP Company Descriptions

Immunic NASDAQ:IMUX

Lifecore Biomedical NASDAQ:LFCR

NRx Pharmaceuticals NASDAQ:NRXP

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERU, IMUX, LFCR, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERU, IMUX, LFCR, and NRXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERU, IMUX, LFCR, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU, IMUX, LFCR, and NRXP Company Descriptions

Immunic NASDAQ:IMUX

Lifecore Biomedical NASDAQ:LFCR

NRx Pharmaceuticals NASDAQ:NRXP

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools